Global Triamcinolone Acetonide Nasal Market Size, Share and Trends Analysis Report, By Type (200 mcg and 400 mcg) and By Application (Adults and Adolescents) Forecast 2022-2028

The global triamcinolone acetonide nasal market is anticipated to grow at a significant CAGR of 4.5% during the forecast period 2022-2028. The growth of the market is attributed to the rising cases of nasal problems and other inflammatory disorders associated with allergies and asthma such as perennial allergic rhinitis. According to World Health Organization (WHO), asthma is a significant non-communicable disease (NCD) that affects both children and adults. In 2019, asthma afflicted an estimated 262 million individuals, resulting in 461000 fatalities. The most frequent chronic condition among children is asthma. Inhaled medicine can help patients with asthma manage their symptoms and live a normal, active life. According to NCBI, Allergic rhinitis is a chronic upper airway inflammatory disease that affects approximately 60 million adults and children in the US.

The rising incidence of respiratory allergies, the ageing population, and technological improvements are some of the primary drivers driving demand for triamcinolone acetonide nasal treatments globally. In addition, the prevalence of asthma, COPD, and hay fever has increased significantly. Increased understanding of the numerous types of drugs available to treat sinusitis is predicted to have a substantial impact on the market. For instance, in January 2022, Glenmark Pharmaceuticals Ltd. announced that its fully-owned Swiss subsidiary Glenmark Specialty S.A. received approval for Ryaltris, a nasal spray fixed-dose prescription drug from the US Food and Drug Administration (FDA). It is used for the treatment of seasonal allergic rhinitis. For instance, in January 2021, JB Chemicals and Pharmaceuticals Ltd. announced that the US FDA has approved an abbreviated new drug application (ANDA) for Loratadine tablets USP 10 mg in the US market. The medication is used to treat pollen-induced allergic rhinitis and upper respiratory tract allergies.

There are two types of triamcinolone acetonide nasal sprays present in the market 200 mcg and 400 mcg. Among these two, the 200 mcg is expected to face segmental growth in the global triamcinolone acetonide nasal market due to various benefits offered by it such as relief from inflammatory conditions, nasal problems, perennial allergic rhinitis and many more. The 400-mcg variant is more efficient but does have more side effects such as burning or stinging sensations in your nose, headaches, and nausea.

Some major players in the market include Perrigo Co. PLC, Rising Pharma Holdings Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd. among others. The market players are helping significantly in the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay in the competition of the market. For instance, in June 2021, Bayer Healthcare LLC announced that it has received the approval of Astepro (azelastine hydrochloride nasal spray, 0.15%) from the US FDA. It is used for the treatment of seasonal and perennial allergic rhinitis for adults and children six years of age and older. For instance, in November 2021, Revelation Biosciences Inc. announced the initiation for its Phase 1b proof-of-concept nasal allergen challenge clinical study (RVL-CLR01) to evaluate the potential utility of REVTx-99 for treating patients with allergic rhinitis and patients with chronic nasal congestion without polyps. The study is being conducted in Australia and is enrolling individuals 18 to 55 years of age with a presumed history of allergic rhinitis to ryegrass pollen.

 

Market Coverage

• The market number available for – 2022-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Perrigo Co. PLC, Rising Pharma Holdings Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd. among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Triamcinolone Acetonide Nasal Market Report by Segment

By Type

• 200 mcg
• 400 mcg

By Application

• Adults
• Adolescents

Global Triamcinolone Acetonide Nasal Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa